Clinical and Virologic Outcomes After Changes in First Antiretroviral Regimen at 7 Sites in the Caribbean, Central and South America Network

scientific article

Clinical and Virologic Outcomes After Changes in First Antiretroviral Regimen at 7 Sites in the Caribbean, Central and South America Network is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1097/QAI.0000000000000817
P932PMC publication ID4712722
P698PubMed publication ID26761273

P50authorMarcelo WolffQ55523651
Jean-William PapeQ67590873
Denis PadgettQ83392975
Catherine C. McGowanQ83393370
Peter Francis RebeiroQ42707320
P2093author name stringSandra Wagner Cardoso
Bryan E Shepherd
Juan Echevarria
Carina Cesar
Juan Sierra-Madero
Claudia Cortés
Caribbean, Central and South America Network for HIV Epidemiology
P2860cites workPredictors of failure of first-line antiretroviral therapy in HIV-infected adults: Indian experienceQ50145094
Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (Q50803241
Confounding by indicationQ71502678
Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individualsQ22242705
Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studiesQ24597052
Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the CaribbeanQ28749991
Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin AmericaQ33598309
Correcting mortality for loss to follow-up: a nomogram applied to antiretroviral treatment programmes in sub-Saharan AfricaQ33803701
Outcomes after virologic failure of first-line ART in South AfricaQ33985234
Estimating loss to follow-up in HIV-infected patients on antiretroviral therapy: the effect of the competing risk of death in Zambia and SwitzerlandQ34113515
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort studyQ34474961
Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studiesQ34667707
Rates and factors associated with major modifications to first-line combination antiretroviral therapy: results from the Asia-Pacific regionQ34804309
Efficacy of second-line antiretroviral therapy among people living with HIV/AIDS in Asia: results from the TREAT Asia HIV observational databaseQ34977431
Splines for trend analysis and continuous confounder control.Q35335098
Long-term antiretroviral treatment outcomes in seven countries in the CaribbeanQ35823246
A causal framework for understanding the effect of losses to follow-up on epidemiologic analyses in clinic-based cohorts: the case of HIV-infected patients on antiretroviral therapy in AfricaQ35963111
Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008.Q36661756
National review of first treatment change after starting highly active antiretroviral therapy in antiretroviral-naïve patientsQ36802662
Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programmeQ36936569
Early mortality and cause of deaths in patients using HAART in Brazil and the United StatesQ37215053
Risk factors associated with virologic failure in HIV- infected patients receiving antiretroviral therapy at a public hospital in PeruQ37481106
Cohort studies: to what extent can they inform treatment guidelines?Q37649350
Management of antiretroviral failure and resistance in developing countriesQ37667831
Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysisQ37982191
Treatment outcomes of recommended first-line antiretroviral regimens in resource-limited clinicsQ37985378
Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapyQ38400338
Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patientsQ38448897
Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from UgandaQ38869763
Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backboneQ39422861
Incidence of modifying or discontinuing first HAART regimen and its determinants in a cohort of HIV-infected patients from Rio de Janeiro, BrazilQ39851943
Nuke-sparing regimens as a main simplification strategy and high level of toxicity resolution after antiretroviral switch: the SWITCHART StudyQ41661280
Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimensQ43683920
Impact of antiretroviral regimen switches on adherenceQ44198906
Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009.Q44982299
Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy--implications for sustained efficacy of ART in resource-limited settingsQ45774389
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countriesQ46391119
Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries.Q46425339
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectvirologyQ7215
CaribbeanQ664609
anti-retroviral agentQ50430310
P304page(s)102-110
P577publication date2016-01-01
P1433published inJournal of Acquired Immune Deficiency SyndromesQ6294722
P1476titleClinical and Virologic Outcomes After Changes in First Antiretroviral Regimen at 7 Sites in the Caribbean, Central and South America Network
P478volume71

Reverse relations

cites work (P2860)
Q33834625A decade of HAART in Latin America: Long term outcomes among the first wave of HIV patients to receive combination therapy
Q52661543Durability of Efavirenz Compared With Boosted Protease Inhibitor-Based Regimens in Antiretroviral-Naïve Patients in the Caribbean and Central and South America.
Q37653463Effectiveness and Risk Factors for Virological Outcome of Raltegravir-Based Therapy for Treatment-Experienced HIV-Infected Patients.
Q38377004Effectiveness of second-line antiretroviral therapy: the impact of drug switches
Q90283351HIV Care continuum Outcomes: Can Ethiopia Meet the UNAIDS 90-90-90 Targets?
Q58769869Immunological failure in HIV-infected adults from 2003 to 2015 in Southwest Ethiopia: a retrospective cohort study

Search more.